Biotech's Boom Suffers a Setback in March April 01, 2014 | Press Release

Investors Flock to Biotech March 03, 2014 | Press Release

Biotech IPOs Off to a Strong Start in 2014 February 03, 2014 | Press Release

  See all News
Sign up for a free subscription to The Burrill Weekly Brief 
Sign up to receive email notifications about our upcoming events and news.

Biotech Visionary, G. Steven Burrill receives DiNA

November 14, 2008

SAN FRANCISCO – November 14, 2008 – At the BayBio Pantheon Awards Dinner held here last night, G. Steven Burrill, CEO, Burrill & Company, a San Francisco based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media, received the 2008 DiNA Award for Lifetime Achievement. The BayBio DiNA awards are presented to the industry executives and stakeholders who have played a key role in life sciences advancements in Northern California. Mr. Burrill joins notable past Lifetime Achievement Awardees including: Dr. Ronald Cape, Dr. William Rutter, Dr. Herbert Boyer, Robert Swanson, Dr. George Rathmann and Dr. Alejandro Zaffaroni.
Mr. Burrill has been involved in the growth and prosperity of the biotechnology industry for over 42 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Boards of Pharmasset (NASDAQ: VRUS) and BioImagene, and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (NASDAQ: DEPO), Intranasal, Phytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50).
Additionally, he serves as Chairman of the Board of the Campaign for Medical Research as well as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MAYBAC). He also serves on the Purdue Discovery Park External Advisory Committee as well as the editorial board of the Journal of Commercial Biotechnology and serves as an advisor to University of Illinois Institute for Genomic Biology, University of Wisconsin—College of Agriculture and Life Sciences, Carnegie Mellon, and Duke University, and is an adjunct professor at University of California, San Francisco.

In accepting the award Mr. Burrill commented: “It has certainly been a real privilege to be involved in the start and long term growth of a very exciting and vibrant industry. What gives me the greatest pleasure is that I have had the opportunity to make a difference. If we can all go through life, knowing we’ve made a difference to people, to companies, to governments, to our cities and communities – we will live in a much better world.”

To view the video presentation by BayBio about Mr. Burrill, click here
About BayBio
BayBio is an independent, trade association serving more than 400 members involved in research, development, and commercialization of life science technologies. The staff and services of BayBio are paid primarily through memberships, sponsorships, and event registration fees.
BayBio provides these services through representatives in South San Francisco and through coalition partners in Washington, DC. More info about BayBio can be found at
About Burrill & Company
Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions.
Burrill is also the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publishes a range of bio-intelligence reports including the monthly Burrill Biotechnology Report and annual “State of the Industry” report, the 22nd Edition is entitled Biotech 2008: Life Sciences – A 20/20 Vision to 2020.


Back to News list  
News Archive: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All